Related Experiment Video
Updated: Aug 16, 2026

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
Published on: July 8, 2011
Co-expression of the complement regulatory proteins human DAF and CD59 with an IRES-mediated dicistronic mammalian
Li Xu1, Huanjie Shao, Wenlan Wu
1State Key Laboratory of Virology, College of Life Science, Wuhan University, P.R. China.
Insights
Combining human complement regulatory proteins, decay accelerating factor (DAF/CD55) and protectin CD59, via a novel vector, effectively protects cells against complement-mediated damage. This strategy shows promise for preventing hyperacute rejection in xenotransplantation.
Area of Science:
- Biotechnology
- Immunology
- Gene Therapy
Background:
- Human complement regulatory proteins (hCRPs), including decay accelerating factor (DAF/CD55) and protectin CD59, are crucial for preventing host complement-mediated damage.
- Hyperacute rejection in xenotransplantation is a major barrier, often mediated by complement activation.
Purpose of the Study:
- To develop a strategy for co-expressing DAF and CD59 in non-human cells to enhance protection against human complement.
- To evaluate the efficacy of a dicistronic expression vector utilizing the encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) for co-delivering hCD59 and hDAF.
Main Methods:
- Construction of a dicistronic mammalian expression vector (pcDNA3-CD59IRESDAF).
- Stable transfection of NIH/3T3 cells and confirmation of co-expression using RT-PCR, Western blotting, and immunofluorescence microscopy.
- Assessment of cellular protection via human complement-mediated cytolysis assays.
Main Results:
- The EMCV IRES facilitated efficient co-expression of hCD59 and hDAF on the cell surface.
- Co-expressed DAF and CD59 provided significantly greater protection against complement-mediated cytolysis compared to individual proteins.
- The pcDNA3-CD59IRESDAF vector demonstrated effective control of complement activation.
Conclusions:
- Internal ribosomal entry site (IRES)-containing polycistronic vectors enhance multi-gene delivery efficiency and effectiveness.
- The pcDNA3-CD59IRESDAF construct holds therapeutic potential for controlling complement activation and preventing hyperacute rejection in clinical gene therapy applications.
- Co-expression of DAF and CD59 is a superior strategy for combating complement-mediated damage in xenotransplantation.
Abstract:
The human complement regulatory proteins (hCRPs) decay accelerating factor (DAF/CD55) and protectin CD59 transfected into non-human cells could confer protection against human complement. The combination of DAF and CD59 would be an effective strategy to help overcome host complement-induced hyperacute rejection in xenotransplantation. We constructed a dicistronic mammalian expression vector pcDNA3-CD59IRESDAF by using the internal ribosomal entry sites (IRES) of the encephalomyocarditis virus (EMCV). RT-PCR, Western blotting and immunofluorescence microscopic analysis demonstrated that the EMCV IRES allowed for efficient co-expression of hCD59 and hDAF on the surface of NIH/3T3 cells transfected stably with pcDNA3-CD59IRESDAF. Human complement-mediated cytolysis assays showed that co-expressed DAF and CD59 proteins could provide more significant protection against complement-mediated cytolysis than either hCD59 or hDAF alone. These results suggest that IRES containing polycistronic vector should improve the efficiency and effectiveness of multi-gene delivery and that the construct pcDNA3-CD59IRESDAF vector has potential therapeutic value for effectively controlling complement activation and for preventing hyperacute rejection in clinical gene therapy.
Related Concept Videos
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Regulation of the Unfolded Protein Response

